Cargando…

TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis

Aberrant activation of nuclear factor-κB (NF-κB) allows cancer cells to escape chemotherapy-induced cell death and acts as one of the major mechanisms of acquired chemoresistance in cervical cancer. TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress,...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Shan, Lu, Jiaxiong, Zhao, Yanling, Woodfield, Sarah E., Zhang, Huiyuan, Xu, Xin, Yu, Yang, Zhao, Jing, Bieerkehazhi, Shayahati, Liang, Haoqian, Yang, Jianhua, Zhang, Fuchun, Sun, Surong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464900/
https://www.ncbi.nlm.nih.gov/pubmed/28430599
http://dx.doi.org/10.18632/oncotarget.16895
_version_ 1783242859358453760
author Guan, Shan
Lu, Jiaxiong
Zhao, Yanling
Woodfield, Sarah E.
Zhang, Huiyuan
Xu, Xin
Yu, Yang
Zhao, Jing
Bieerkehazhi, Shayahati
Liang, Haoqian
Yang, Jianhua
Zhang, Fuchun
Sun, Surong
author_facet Guan, Shan
Lu, Jiaxiong
Zhao, Yanling
Woodfield, Sarah E.
Zhang, Huiyuan
Xu, Xin
Yu, Yang
Zhao, Jing
Bieerkehazhi, Shayahati
Liang, Haoqian
Yang, Jianhua
Zhang, Fuchun
Sun, Surong
author_sort Guan, Shan
collection PubMed
description Aberrant activation of nuclear factor-κB (NF-κB) allows cancer cells to escape chemotherapy-induced cell death and acts as one of the major mechanisms of acquired chemoresistance in cervical cancer. TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress, is required for tumor cell viability and survival. Herein, we examined whether TAK1 inhibition is a potential therapeutic strategy for treating cervical cancer. We found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of Dox in a panel of cervical cancer cell lines. Treatment with 5Z-7-oxozeaenol hindered Dox-induced NF-κB activation and promoted Dox-induced apoptosis in cervical cancer cells. Moreover, 5Z-7-oxozeaenol showed similar effects in both positive and negative human papillomavirus-infected cervical cancer cells. Taken together, our results provide evidence that TAK1 inhibition significantly sensitizes cervical cancer cells to chemotherapy-induced cell death and supports the use of TAK1 inhibitor with current chemotherapies in the clinic for patients with refractory cervical cancer.
format Online
Article
Text
id pubmed-5464900
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54649002017-06-21 TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis Guan, Shan Lu, Jiaxiong Zhao, Yanling Woodfield, Sarah E. Zhang, Huiyuan Xu, Xin Yu, Yang Zhao, Jing Bieerkehazhi, Shayahati Liang, Haoqian Yang, Jianhua Zhang, Fuchun Sun, Surong Oncotarget Research Paper Aberrant activation of nuclear factor-κB (NF-κB) allows cancer cells to escape chemotherapy-induced cell death and acts as one of the major mechanisms of acquired chemoresistance in cervical cancer. TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress, is required for tumor cell viability and survival. Herein, we examined whether TAK1 inhibition is a potential therapeutic strategy for treating cervical cancer. We found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of Dox in a panel of cervical cancer cell lines. Treatment with 5Z-7-oxozeaenol hindered Dox-induced NF-κB activation and promoted Dox-induced apoptosis in cervical cancer cells. Moreover, 5Z-7-oxozeaenol showed similar effects in both positive and negative human papillomavirus-infected cervical cancer cells. Taken together, our results provide evidence that TAK1 inhibition significantly sensitizes cervical cancer cells to chemotherapy-induced cell death and supports the use of TAK1 inhibitor with current chemotherapies in the clinic for patients with refractory cervical cancer. Impact Journals LLC 2017-04-06 /pmc/articles/PMC5464900/ /pubmed/28430599 http://dx.doi.org/10.18632/oncotarget.16895 Text en Copyright: © 2017 Guan et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Guan, Shan
Lu, Jiaxiong
Zhao, Yanling
Woodfield, Sarah E.
Zhang, Huiyuan
Xu, Xin
Yu, Yang
Zhao, Jing
Bieerkehazhi, Shayahati
Liang, Haoqian
Yang, Jianhua
Zhang, Fuchun
Sun, Surong
TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
title TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
title_full TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
title_fullStr TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
title_full_unstemmed TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
title_short TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
title_sort tak1 inhibitor 5z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464900/
https://www.ncbi.nlm.nih.gov/pubmed/28430599
http://dx.doi.org/10.18632/oncotarget.16895
work_keys_str_mv AT guanshan tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT lujiaxiong tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT zhaoyanling tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT woodfieldsarahe tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT zhanghuiyuan tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT xuxin tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT yuyang tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT zhaojing tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT bieerkehazhishayahati tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT lianghaoqian tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT yangjianhua tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT zhangfuchun tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis
AT sunsurong tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis